TrialESMO open2026

First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study.

M Schmidt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.